Cargando…
ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice
Obesity is one of the most prevalent metabolic diseases in the Western world and correlates directly with insulin resistance, which may ultimately culminate in type 2 diabetes (T2D). We sought to ascertain whether the human metalloproteinase A Disintegrin and Metalloproteinase 19 (ADAM19) correlates...
Autores principales: | Weerasekera, Lakshini, Rudnicka, Caroline, Sang, Qing-Xiang, Curran, Joanne E., Johnson, Matthew P., Moses, Eric K., Göring, Harald H. H., Blangero, John, Hricova, Jana, Schlaich, Markus, Matthews, Vance B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318628/ https://www.ncbi.nlm.nih.gov/pubmed/28265178 http://dx.doi.org/10.1155/2017/7281986 |
Ejemplares similares
-
The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice
por: Herat, Lakshini, et al.
Publicado: (2017) -
Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes
por: Matthews, Jennifer, et al.
Publicado: (2021) -
SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020) -
A cautionary note for researchers treating mice with the neurotransmitter norepinephrine
por: Matthews, Vance B., et al.
Publicado: (2018) -
The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)